# Nuclide record i-131-tositumomab (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/i-131-tositumomab/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "i-131-tositumomab" ;
  schema:name "Iodine-131 tositumomab"@en ;
  schema:alternateName "Bexxar"@en, "tositumomab and I-131 tositumomab"@en, "Bexxar" ;
  schema:description "A cancer-targeting antibody carrying a radioactive form of iodine was used, as a single course, to treat a type of blood cancer called non-Hodgkin lymphoma. The manufacturer stopped selling it in 2014 because too few patients were using it."@en ;
  schema:url <https://nuclide.cc/drugs/i-131-tositumomab/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pipelinereview.com/gsk-to-discontinue-manufacture-and-sale-of-the-bexxar-therapeutic-regimen-tositumomab-and-iodine-i-131-tositumomab/>, <https://static1.squarespace.com/static/55550f38e4b0884d8d80118e/t/5565d1aae4b0660ba5b932e2/1432736170326/2014+-+Nov+-+JAMA+IM+-+Withdrawal+of+Drugs+for+Commercial+Reasons+-+Tositumomab.pdf>, <https://openmedscience.com/the-rise-and-fall-of-iodine-131-tositumomab-bexxars-story/> ;
  nuclide:status "withdrawn" ;
  nuclide:tag "radioimmunotherapy", "lymphoma", "withdrawn", "beta and gamma emitter" ;
  nuclide:modality "radioimmunotherapy" ;
  nuclide:approval "US 2003: CD20-positive relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin lymphoma progressing during or after rituximab therapy", "CA 2005: Same indication as the US approval" ;
  nuclide:related <https://nuclide.cc/drugs/ibritumomab-tiuxetan/>, <https://nuclide.cc/drugs/rituximab/>, <https://nuclide.cc/isotopes/i-131/>, <https://nuclide.cc/isotopes/y-90/> ;
  nuclide:indications <https://nuclide.cc/indications/follicular-lymphoma/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioimmunotherapy/> ;
  nuclide:targets <https://nuclide.cc/targets/cd20/> .